> The product would be commercialized under the brand name UZEDY
Kåre Schultz, CEO of Teva, spoke today at the Q2 earnings call of Teva:
Answering questions from participants, M. Schultz said: “We still expect to launch UZEDY, which is the brand name for the risperidone LAI, first half of next year.”
He added later that this “risperidone long-acting product looks extremely good from a clinical point of view, both in terms of efficacy and safety”, and that “it will be a major improvement compared to long acting antipsychotics that you can do subcutaneously, and it works for one or two months. So that is going to be really nice to get that finally approved and launched next year.”